Article
Seraprevir and sofosbuvir for treatment of chronic hepatitis C virus infection: A single-arm, open-label, phase 3 trial.
Journal of gastroenterology and hepatology - 1 Sept 2021
Kong Fei, Wen Xiaoyu, Wen Xiaofeng, Wang Xiaozhong, Wu Guicheng, Lin Shide, Wang Li, Xing Huichun, Yan Xuebing, Zheng Sujun, Ning Qin, Wang Zheng, Zhang Liaoyun, Lin Jianmei, Tong Zhaowei, Huang Chengyu, Su Minghua, Tong Lixin, Jia Jidong, Xin Yongning, Zhu Qingjing, Wang Jing, Chen Li, Li Xiaowen, Wu Xuegang, Niu Duan, Liu Quan, Wei Wei, Zhang Yuexin, Li Guangming, Niu Junqi
Abstract excerpt
BACKGROUND AND AIM: This single-arm, open-label, multicenter, phase 3 trial evaluated the efficacy and safety of seraprevir, an hepatitis C virus (HCV) nonstructural protein 3/4A (NS3/4A) inhibitor, combined with sofosbuvir for treating Chinese patients with chronic HCV infection without cirrhosis. METHODS: Treatment-naive or interferon-experienced adult patients without cirrhosis were treated with a universal,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.